Choosing the Right Biotech Exit Strategy

The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to continue funding a promising, new product and when to call it quits.Tune in for insights into:Why a “fast to failure” mentality is key to a successful development pipelineHow leaders can redivert organizational resources after ending a programWhy drug development failures can ultimately lead to positive outcomes

In this episode of BDO’s Health & Life Sciences Rx Podcast, BDO’s Todd Berry sits down with leaders from Universal Cells, Fortress Biotech, and McDermott Will & Emery to discuss how leaders in biotech can assess the current M&A and IPO landscape to choose the right exit strategy for their organization.

Nurses are already leading patient care innovation, but their full potential has yet to be unleashed. Listen to the latest episode of BDO’s Health & Life Sciences Rx Podcast to hear from the women working to change that.

Tune in for insights on:The convergence of senior healthcare and housing—and implications for healthcare REITs and private equity professionalsThe operational and hospitality components that make senior housing and skilled nursing facilities attractive investment prospectsThe importance of providing education to seniors—and their caregivers—on all available housing and care models 

Seniors—the fastest-growing U.S. age demographic—are poised to make up more than 20 percent of the U.S. population by 2029. And they’re moving to the driver’s seat of care. Now, they’re demanding elder care more rooted in empathy and designed on their own terms—and in their preferred environment. With these shifts, new types of entities—including those building alternative types of senior care communities—will form, and health organizations will need to create and fill new types of roles.

The growth of the aging population—and providing proper care to that population—is an urgent challenge facing the global economy. Although each market has its own regulatory and cultural intricacies, we’ve found an antidote becoming more common across borders: an empathy-based elder care system focused on preserving independence.

With KKR's $10 billion purchase of Envision Healthcare this summer, the largest healthcare buyout deal since the financial crisis, private equity's appetite for healthcare deals might well be stronger than ever. Meanwhile, with Amazon's emerging healthcare arm and an imminent deal between CVS and Aetna, providers are turning to digital innovation to help navigate industry disruption. Tune into the full episode for a range of insights, including:What's triggering deal flow and high valuations across the health-care space.How healthcare companies are capitalizing on new data sources.Why elder-care providers are increasingly focused on preserving independence.

Tune in to the full episode to hear about:Why industry outsiders are entering healthcareHow these outsiders are uniquely suited to improve customer service and lower costsWhat business strategies have the most potential to create growth

Tune in to the full episode to hear about:The exponential growth in genetic testing and genomic technologiesNew drug therapies that are based on live organismsInnovation in technology platforms connecting patients, providers, payers, industry, and investors

Dr. Karen De Salvo—Professor of Medicine & Population Health, UT Austin Dell Medical School, former US Assistant Secretary for Health (Acting) & National Coordinator for Health IT—talks with Patrick Pilch, Managing Director and National Leader of BDO’s healthcare advisory practice, about the future of digital health and how data can be leveraged for public health purposes, population health management, planning, and disaster recovery.